Group One Trading’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-198,500
| Closed | -$4.26M | – | 7759 |
|
|
2026
Q1 | $4.26M | Buy |
198,500
+47,800
| +32% | +$674K | 0.01% | 1427 |
|
|
2025
Q4 | $1.4M | Buy |
150,700
+149,900
| +18,738% | +$1.25M | ﹤0.01% | 2592 |
|
|
2025
Q3 | $5.64K | Sell |
800
-3,100
| -79% | -$21.3K | ﹤0.01% | 7479 |
|
|
2025
Q2 | $25.4K | Sell |
3,900
-7,200
| -65% | -$49.5K | ﹤0.01% | 6111 |
|
|
2025
Q1 | $88K | Buy |
11,100
+10,400
| +1,486% | +$112K | ﹤0.01% | 4690 |
|
|
2024
Q4 | $8.87K | Sell |
700
-29,400
| -98% | -$409K | ﹤0.01% | 6158 |
|
|
2024
Q3 | $419K | Sell |
30,100
-37,200
| -55% | -$531K | ﹤0.01% | 2995 |
|
|
2024
Q2 | $927K | Buy |
67,300
+62,700
| +1,363% | +$917K | ﹤0.01% | 2052 |
|
|
2024
Q1 | $76K | Buy |
4,600
+400
| +10% | +$5.99K | ﹤0.01% | 4375 |
|
|
2023
Q4 | $61.3K | Sell |
4,200
-5,800
| -58% | -$70.3K | ﹤0.01% | 4905 |
|
|
2023
Q3 | $123K | Buy |
10,000
+4,800
| +92% | +$62.6K | ﹤0.01% | 4268 |
|
|
2023
Q2 | $62.1K | Buy |
+5,200
| New | +$67.9K | ﹤0.01% | 5086 |
|
|
2023
Q1 | – | Sell |
-176,900
| Closed | -$3.81M | – | 7332 |
|
|
2022
Q4 | $3.81M | Sell |
176,900
-400
| -0.2% | -$8.2K | 0.01% | 1333 |
|
|
2022
Q3 | $3.55M | Buy |
177,300
+175,300
| +8,765% | +$3.73M | 0.01% | 1444 |
|
|
2022
Q2 | $36K | Buy |
+2,000
| New | +$20.7K | ﹤0.01% | 5833 |
|
Other funds holding DAWN
Group One Trading's DAWN Position: Q1 2026 in Review
Group One Trading sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 253,143 shares — an estimated $3.57M sold.
Group One Trading first reported a position in DAWN in Q3 2022 and held it in 8 quarters. The position peaked at $2.36M in Q4 2025. 208 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.
- Group One Trading reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Group One Trading sold 253,143 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3.57M.
- Group One Trading first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 8 quarters.
- Group One Trading's Day One Biopharmaceuticals position peaked at $2.36M in Q4 2025.
- 208 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.